Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

NCT05511623 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: tislelizumab
OTHER: concurrent chemoradiotherapy

Sponsor

First Affiliated Hospital of Guangxi Medical University